Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression
- PMID: 2039768
Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression
Abstract
Transcriptional activation of gene expression directed by the long terminal repeat (LTR) of the human immunodeficiency virus type 1 (HIV-1) requires both the Tat activation response element (TAR) and the Tat protein. Mutants lacking a functional tat gene are not able to replicate. An approach we have used to suppress HIV-1 gene expression is based on the controlled overexpression of multimerized TAR sequences, which results in the sequestration of one or more components of the Tat response. Since Tat has no known cellular analog, a modified HIV-1 LTR, which is highly induced by the presence of Tat, was used to promote the expression of the multimerized TAR (poly-TAR) specifically in the presence of Tat. Cotransfection of an HIV-1 LTR-controlled poly-TAR plasmid with LTR-Tat and LTR-CAT plasmids inhibited the level of the reporter gene activity (CAT) as much as 97%. The downregulation of HIV-1 gene expression observed was dependent on the quantity of transfected poly-TAR as well as the number of tandem TAR repeats expressed per unit transcript. Similar constructs lacking either LTR upstream sequences or the TAR sequence had no significant effect, suggesting that the competitive effect was mediated at the RNA level and that it was the nascent RNA, rather than DNA, that was recognized by the Tat protein. Tat-regulated production of the poly-TAR transcript provides a means for dissecting the mechanism of Tat-mediated trans-activation of the HIV-1 LTR. The ability to regulate a viral inhibitory gene so that it is expressed only when needed should prove useful in devising an antiviral strategy through gene therapy.
Similar articles
-
Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.Gene Ther. 1995 Jun;2(4):269-78. Gene Ther. 1995. PMID: 7552987
-
Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.New Biol. 1991 Aug;3(8):759-68. New Biol. 1991. PMID: 1931822
-
Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.Nature. 1990 Jun 14;345(6276):640-2. doi: 10.1038/345640a0. Nature. 1990. PMID: 2190099
-
RNA-sequence-mediated gene regulation in HIV-1.Infect Agents Dis. 1994 Apr-Jun;3(2-3):68-76. Infect Agents Dis. 1994. PMID: 7812657 Review.
-
Tackling Tat.J Mol Biol. 1999 Oct 22;293(2):235-54. doi: 10.1006/jmbi.1999.3060. J Mol Biol. 1999. PMID: 10550206 Review.
Cited by
-
Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators.J Virol. 1992 Apr;66(4):2000-7. doi: 10.1128/JVI.66.4.2000-2007.1992. J Virol. 1992. PMID: 1312617 Free PMC article.
-
Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs.Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7272-6. doi: 10.1073/pnas.92.16.7272. Proc Natl Acad Sci U S A. 1995. PMID: 7638180 Free PMC article.
-
Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes.J Exp Med. 1996 Aug 1;184(2):315-24. doi: 10.1084/jem.184.2.315. J Exp Med. 1996. PMID: 8760785 Free PMC article.
-
Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.Inflamm Res. 1995 Jan;44(1):11-5. doi: 10.1007/BF01630480. Inflamm Res. 1995. PMID: 7664023 Review. No abstract available.
-
Gene therapy for infectious diseases.Clin Microbiol Rev. 1998 Jan;11(1):42-56. doi: 10.1128/CMR.11.1.42. Clin Microbiol Rev. 1998. PMID: 9457428 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous